12 Cheap Healthcare Stocks to Buy Now

Page 6 of 10

5. Bristol-Myers Squibb Company (NYSE:BMY

Forward PE Ratio: 7.38 

Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical leader, specializes in oncology, immunology, cardiovascular, hematology, and neuroscience therapies, with blockbuster drugs including Eliquis and Opdivo.

In July 2025, Bristol-Myers Squibb Company (NYSE:BMY) partnered with Bain Capital to launch a new independent biotech focused on autoimmune disease therapies. The spinout, funded with $300 million, includes five immunology programs targeting pathways such as TLR7/8, TYK2, and IL2. BMS retains a 20% stake, anticipating long-term benefits through milestones and royalties.

BMY is also advancing immunotherapy for lung cancer. In September 2025, it and BioNTech reported promising Phase II results for BNT327/pumitamig in small cell lung cancer, achieving a 76% tumor reduction rate. The therapy is now in Phase III trials, supported by a collaboration valued at up to $11.1 billion. In addition, updated Phase I data for the PRMT5 inhibitor BMS-986504 in non-small cell lung cancer showed a 29% response rate in patients with MTAP gene deletions, with biomarker strategies guiding further development.

Oncology innovation continues with the July 2025 launch of a clinical trial for Iza-bren, an investigational breast cancer therapy targeting patients unsuitable for conventional immunotherapies. The business is also leveraging artificial intelligence to accelerate drug discovery and improve clinical trial efficiency, enhancing both pipeline innovation and cost effectiveness.

Despite these new initiatives, Bristol-Myers Squibb Company (NYSE:BMY) maintains strong revenue from established products. In Q2 2025, Eliquis sales rose 8% to $3.7 billion, while Opdivo revenue grew 7% to $2.6 billion, underscoring the continued strength of its legacy brands alongside an expanding pipeline of next-generation therapies.

Page 6 of 10